Patents by Inventor Haiyong Han
Haiyong Han has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230324431Abstract: A method of estimating a speed of an object in real-time includes acquiring from an acceleration sensor mounted on the object a first original acceleration signal indicative of an acceleration of the object in a direction parallel to a travelling direction of the object, filtering the first original acceleration signal to remove noise to produce a first filtered acceleration signal, down-sampling the first filtered acceleration signal to obtain a first optimized acceleration signal, and calculating an estimated speed value of the object along the direction parallel to the travelling direction of the object based on the first optimized acceleration signal.Type: ApplicationFiled: April 4, 2023Publication date: October 12, 2023Inventors: Wenjun LI, Haiyong HAN, Xiaoyuan MA, Gang CHENG, Mark RHODES
-
Publication number: 20220135095Abstract: A train speed estimation device and method are disclosed. Vibration in a natural frequency band experienced by a train as it advances is sampled by means of first and second sensors at the same sampling frequency, to obtain a first set and a second set of sampling signals respectively; a first set and a second set of vibration signals are obtained on the basis of the first set and second set of sampling signals respectively, and the first set and second set of vibration signals are subjected to cross-correlation analysis, to obtain a target sampling difference; and a train speed is calculated on the basis of the target sampling difference. The train speed estimation device and method according to the present disclosure can precisely monitor the real-time train speed without relying on any speed sensor or GNSS.Type: ApplicationFiled: September 26, 2021Publication date: May 5, 2022Inventors: Wenjun Li, Haiyong Han, Gang Cheng, Jim Wei
-
Patent number: 10322127Abstract: Methods of tests that assess the expression of DPC4 (SMAD4) to identify subjects with pancreatic cancer that are likely or unlikely to respond to treatment with BTK inhibitors; methods of treating subjects based on identification of the subjects as likely to respond to treatment with BTK inhibitors; therapeutic targets for cancers, particularly cancers with inactivated DPC4 gene or protein; methods of screening of new therapeutic agents using the target; pharmaceutical composition comprising BTK inhibitors, such as PCI-32765 or derivatives thereof, for cancer treatment; and kits that facilitate the performance of the methods are disclosed.Type: GrantFiled: June 20, 2016Date of Patent: June 18, 2019Assignee: The Translational Genomics Research InstituteInventors: Haiyong Han, Daniel Von Hoff, Caroline H. Diep, Hongwei Yin
-
Publication number: 20160346285Abstract: Methods of tests that assess the expression of DPC4 (SMAD4) to identify subjects with pancreatic cancer that are likely or unlikely to respond to treatment with BTK inhibitors; methods of treating subjects based on identification of the subjects as likely to respond to treatment with BTK inhibitors; therapeutic targets for cancers, particularly cancers with inactivated DPC4 gene or protein; methods of screening of new therapeutic agents using the target; pharmaceutical composition comprising BTK inhibitors, such as PCI-32765 or derivatives thereof, for cancer treatment; and kits that facilitate the performance of the methods are disclosed.Type: ApplicationFiled: June 20, 2016Publication date: December 1, 2016Applicant: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTEInventors: Haiyong HAN, Daniel VON HOFF, Caroline H. DIEP, Hongwei YIN
-
Patent number: 9371567Abstract: Methods of tests that assess the expression of DPC4 (SMAD4) to identify subjects with pancreatic cancer that are likely or unlikely to respond to treatment with BTK inhibitors; methods of treating subjects based on identification of the subjects as likely to respond to treatment with BTK inhibitors; therapeutic targets for cancers, particularly cancers with inactivated DPC4 gene or protein; methods of screening of new therapeutic agents using the target; pharmaceutical composition comprising BTK inhibitors, such as PCI-32765 or derivatives thereof, for cancer treatment; and kits that facilitate the performance of the methods are disclosed.Type: GrantFiled: April 19, 2011Date of Patent: June 21, 2016Assignee: The Translational Genomics Research InstituteInventors: Haiyong Han, Daniel Von Hoff, Caroline Huynh Diep, Hongwei Yin
-
Patent number: 8987309Abstract: A 2-aryl-pyridylazole compound and derivatives useful in slowing the growth of cancer cells are disclosed. Also disclosed are methods of synthesizing the compound, methods of using pharmaceutical compositions containing the compound as an ingredient to slow the growth of cancer cells, and methods of treating cancer patients with pharmaceutical compositions containing the compound as an ingredient.Type: GrantFiled: April 19, 2010Date of Patent: March 24, 2015Assignees: The Translational Genomics Research Institute, The Arizona Board of Regents on behalf of the University of ArizonaInventors: Robert Dorr, Gary Flynn, Haiyong Han, Laurence Hurley, Arthur Y. Shaw
-
Patent number: 8703736Abstract: This invention provides a therapeutic target for pancreatic cancer. The invention further provides methods of screening of new therapeutic agents using the target. The invention also provides a pharmaceutical composition comprising fasudil or derivatives thereof for pancreatic cancer treatment, and a kit comprising such a pharmaceutical composition.Type: GrantFiled: April 4, 2012Date of Patent: April 22, 2014Assignee: The Translational Genomics Research InstituteInventors: Cliff Whatcott, Haiyong Han
-
Publication number: 20130273063Abstract: Methods of tests that assess the expression of DPC4 (SMAD4) to identify subjects with pancreatic cancer that are likely or unlikely to respond to treatment with BTK inhibitors; methods of treating subjects based on identification of said subjects as likely to respond to treatment with BTK inhibitors; therapeutic targets for cancers, particularly cancers with inactivated DPC4 gene or protein; methods of screening of new therapeutic agents using the target; pharmaceutical composition comprising BTK inhibitors, such as PCI-32765 or derivatives thereof, for cancer treatment; and kits that facilitate the performance of the methods are disclosed.Type: ApplicationFiled: April 19, 2011Publication date: October 17, 2013Applicant: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTEInventors: Haiyong Han, Daniel Von Hoff, Caroline Huynh Diep, Hongwei Yin
-
Patent number: 8394742Abstract: This invention is directed to methods for screening and identification of compounds capable of selectively eliminating cancer cells with specific loss-of-function alterations, including but not limited to mutations, deletions, hypermethylations, and other types of gene silencing. This invention is also directed to novel compounds that selectively eliminate cancer cells with specific loss-of-function alterations. Furthermore, this invention is directed to methods for production and therapeutic use of compounds that selectively eliminate cancer cells with specific loss-of-function alterations.Type: GrantFiled: April 14, 2006Date of Patent: March 12, 2013Assignees: The Translation Genomics Research Institute, The Arizona Board of Regents on Behalf of the University of ArizonaInventors: Daniel D. Von Hoff, Haiyong Han, Hong Wang, Gary A. Flynn
-
Publication number: 20120252753Abstract: This invention provides a therapeutic target for pancreatic cancer. The invention further provides methods of screening of new therapeutic agents using the target. The invention also provides a pharmaceutical composition comprising fasudil or derivatives thereof for pancreatic cancer treatment, and a kit comprising such a pharmaceutical composition.Type: ApplicationFiled: April 4, 2012Publication date: October 4, 2012Applicant: TRANSLATIONAL GENOMICS RESEARCH INSTITUTEInventors: Cliff Whatcott, Haiyong Han
-
Publication number: 20120136029Abstract: A 2-aryl-pyridylazole compound and derivatives useful in slowing the growth of cancer cells are disclosed. Also disclosed are methods of synthesizing the compound, methods of using pharmaceutical compositions containing the compound as an ingredient to slow the growth of cancer cells, and methods of treating cancer patients with pharmaceutical compositions containing the compound as an ingredient.Type: ApplicationFiled: April 19, 2010Publication date: May 31, 2012Applicants: UNIVERSITY OF ARIZONA, THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTEInventors: Robert Dorr, Gary Flynn, Haiyong Han, Laurence Hurley
-
Publication number: 20110212929Abstract: Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure: including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein A is a ring moiety selected from: and wherein R1, R2, R3, X, Z, L1, Cycl1, L2 and Cycl2 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.Type: ApplicationFiled: March 18, 2011Publication date: September 1, 2011Inventors: Laurence H. Hurley, Daruka Mahadevan, Haiyong Han, David J. Bearss, Hariprasad Vankayalapati, Sridevi Bashyam, Ruben M. Munoz, Steven L. Warner, Kimiko Della Croce, Daniel D. Von Hoff, Cory L. Grand, James Welsh
-
Patent number: 7816082Abstract: Methods that identify cells as pancreatic cancer cells based on assessing the expression of combinations of target molecules expressed preferentially on pancreatic cancer cells are disclosed. Combinations were initially discovered by microarray analysis and selected based upon tumor specificity, relative lack of cross-reactivity with normal tissues, and applicability as targets of multispecific ligands. The claimed methods encompass measuring the expression of three or more specific target molecules in combination and correlating positive expression of the combination with an identification of the cell as a pancreatic cancer cell.Type: GrantFiled: March 3, 2008Date of Patent: October 19, 2010Assignees: The Arizona Board of Regents on behalf of the University of Arizona, The Translational Genomics Research InstituteInventors: Haiyong Han, Robert J Gillies, David L Morse, Victor J Hruby
-
Publication number: 20090143399Abstract: Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure: including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein A is a ring moiety selected from: and wherein R1, R2, R3, X, Z, L1, Cycl1, L2 and Cycl2 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.Type: ApplicationFiled: August 20, 2007Publication date: June 4, 2009Applicants: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, SUPERGEN, INC.Inventors: Laurence H. Hurley, Daruka Mahadevan, Haiyong Han, David J. Bearss, Hariprasad Vankayalapati, Sridevi Bashyam, Ruben M. Munoz, Steven L. Warner, Kimiko Della Croce, Daniel D. Von Hoff, Cory L. Grand, James Welsh
-
Publication number: 20090137420Abstract: This invention is directed to methods for screening and identification of compounds capable of selectively eliminating cancer cells with specific loss-of-function alterations, including but not limited to mutations, deletions, hypermethylations, and other types of gene silencing. This invention is also directed to novel compounds that selectively eliminate cancer cells with specific loss-of-function alterations. Furthermore, this invention is directed to methods for production and therapeutic use of compounds that selectively eliminate cancer cells with specific loss-of-function alterations.Type: ApplicationFiled: April 14, 2006Publication date: May 28, 2009Inventors: Daniel D. Von Hoff, Haiyong Han, Hong Wang, Gary A. Flynn
-
Publication number: 20090099165Abstract: Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure: including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein A is a ring moiety selected from: and wherein R1, R2, R3, X, Z, L1, Cycl1, L2 and Cycl2 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.Type: ApplicationFiled: April 13, 2007Publication date: April 16, 2009Applicants: Arizona Board of Regents on Behalf of The University of Arizona, Montigen Pharmaceuticals, Inc.Inventors: Laurence H. Hurley, Daruka Mahadevan, Haiyong Han, David J. Bearss, Hariprasad Vankayalapati, Sridevi Bashyam, Ruben M. Munoz, Steven L. Warner, Kimiko Della Croce, Daniel D. Von Hoff, Cory L. Grand, James Welsh
-
Publication number: 20080261818Abstract: Methods that identify cells as pancreatic cancer cells based on assessing the expression of combinations of target molecules expressed preferentially on pancreatic cancer cells are disclosed. Combinations were initially discovered by microarray analysis and selected based upon tumor specificity, relative lack of cross-reactivity with normal tissues, and applicability as targets of multispecific ligands. The claimed methods encompass measuring the expression of three or more specific target molecules in combination and correlating positive expression of the combination with an identification of the cell as a pancreatic cancer cell.Type: ApplicationFiled: March 3, 2008Publication date: October 23, 2008Applicants: UNIVERSITY OF ARIZONA, TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN)Inventors: Haiyong Han, Robert J. Gillies, Victor J. Hruby, David L. Morse
-
Publication number: 20080051414Abstract: Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure: including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein A is a ring moiety selected from: and wherein R1, R2, R3, X, Z, L1, Cycl1, L2 and Cycl2 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.Type: ApplicationFiled: March 1, 2007Publication date: February 28, 2008Applicants: Arizona Board of Regents on Behalf of The University of Arizona, SuperGen,IncInventors: Laurence Hurley, Daruka Mahadevan, Haiyong Han, David Bearss, Hariprasad Vankayalapati, Sridevi Bashyam, Ruben Munoz, Steven Warner, Kimiko Della Croce, Daniel Von Hoff, Cory Grand, James Welsh
-
Publication number: 20070026398Abstract: Using gene expression profiling, the present Invention identifies Protein tyrosine phosphatase IVA member 1 (PRL-1) as a diagnostic marker and therapeutic target for pancreatic cancer. The Invention therefore provides methods for prediction and detection of PRL-1 associated cancers, and evaluation of inhibitors of PRL-1. The Invention also provides a method of treating or preventing pancreatic cancer in a subject.Type: ApplicationFiled: March 3, 2004Publication date: February 1, 2007Inventors: Amanda Farnsworth, Haiyong Han, Hariprasad Vankayalapati, Steven Warner, Daniel Von Hoff, David Bearss
-
Publication number: 20050277658Abstract: Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure: including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein A is a ring moiety selected from: and wherein R1, R2, R3, X, Z, L1, Cycl1, L2 and Cycl2 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.Type: ApplicationFiled: March 29, 2005Publication date: December 15, 2005Applicants: Arizona Board of Regents on behalf of The University of Arizona, Montigen Pharmaceuticals, Inc.Inventors: Laurence Hurley, Daruka Mahadevan, Haiyong Han, David Bearss, Hariprasad Vankayalapati, Sridevi Bashyam, Ruben Munoz, Steven Warner, Kimiko Della Croce, Daniel Von Hoff, Cory Grand